Leerink Partnrs Weighs in on United Therapeutics Co.'s Q1 2024 Earnings (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Analysts at Leerink Partnrs increased their Q1 2024 EPS estimates for United Therapeutics in a research note issued to investors on Wednesday, April 17th. Leerink Partnrs analyst R. Ruiz now anticipates that the biotechnology company will post earnings of $5.93 per share for the quarter, up from their prior forecast of $5.90. Leerink Partnrs currently has a "Outperform" rating on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $23.46 per share. Leerink Partnrs also issued estimates for United Therapeutics' Q2 2024 earnings at $6.32 EPS and Q3 2024 earnings at $7.04 EPS.

Several other analysts have also recently issued reports on UTHR. Wedbush reaffirmed an "outperform" rating and set a $308.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. StockNews.com cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Thursday, April 11th. HC Wainwright reaffirmed a "buy" rating and set a $300.00 price objective on shares of United Therapeutics in a research note on Thursday, February 22nd. The Goldman Sachs Group upgraded shares of United Therapeutics from a "sell" rating to a "neutral" rating and boosted their target price for the company from $213.00 to $215.00 in a report on Monday, February 12th. Finally, SVB Leerink initiated coverage on shares of United Therapeutics in a report on Monday, February 5th. They issued an "outperform" rating and a $330.00 target price on the stock. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $292.67.

United Therapeutics Price Performance

NASDAQ UTHR traded up $1.62 during trading hours on Thursday, hitting $236.93. 476,348 shares of the company's stock traded hands, compared to its average volume of 431,791. United Therapeutics has a 52-week low of $204.44 and a 52-week high of $261.54. The company has a market capitalization of $11.15 billion, a PE ratio of 11.94 and a beta of 0.52. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.41 and a quick ratio of 4.28. The firm's 50-day moving average is $231.20 and its 200-day moving average is $228.44.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company had revenue of $614.70 million during the quarter, compared to analysts' expectations of $575.01 million. During the same quarter in the prior year, the company earned $2.67 EPS. United Therapeutics's revenue was up 25.1% compared to the same quarter last year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Rise Advisors LLC purchased a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $32,000. GAMMA Investing LLC purchased a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $43,000. Neo Ivy Capital Management purchased a new stake in shares of United Therapeutics in the 2nd quarter valued at approximately $48,000. Atlas Capital Advisors LLC purchased a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $51,000. Finally, Northwestern Mutual Wealth Management Co. increased its position in shares of United Therapeutics by 49.6% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 65 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total value of $3,548,850.00. Following the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,756.70. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the sale, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,756.70. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Paul A. Mahon sold 6,000 shares of the stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $215.01, for a total transaction of $1,290,060.00. Following the sale, the executive vice president now owns 36,599 shares in the company, valued at $7,869,150.99. The disclosure for this sale can be found here. In the last three months, insiders have sold 126,190 shares of company stock worth $29,672,157. 12.50% of the stock is currently owned by insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.